Core Insights - Idorsia Ltd has launched a groundbreaking initiative called IMPACT-HTN in collaboration with Stanford Hypertension Center and Duke Heart Center to modernize the management of difficult-to-control hypertension [1][2][4] - The program aims to generate real-world evidence, standardize clinical decision-making, and develop AI-powered tools to improve patient outcomes [1][3][4] - TRYVIO™ (aprocitentan), a new treatment targeting a novel pathway in hypertension, is central to this initiative and has been included in recent clinical practice guidelines [6][16] Company Overview - Idorsia is focused on discovering, developing, and commercializing transformative medicines, with a commitment to improving patient outcomes beyond just medication [4][17] - The company is headquartered in Allschwil, Switzerland, and is listed on the SIX Swiss Exchange under the ticker symbol IDIA [18] Industry Context - Hypertension affects approximately 50% of adults in the US, posing significant health risks including cardiovascular events and premature mortality [2] - The IMPACT-HTN program addresses the challenges faced by patients with difficult-to-control hypertension, who often require multiple medications and face coordination issues [1][2][3] Program Details - The IMPACT-HTN initiative consists of three phases aimed at improving care for patients with difficult-to-control hypertension [1][3] - Key components of the program include a digital care algorithm, a personalized hypertension risk score, and a prospective early patient experience initiative [5]

Core Viewpoint - Idorsia Ltd announces the appointment of Dr. Srishti Gupta as the new CEO effective July 1, 2025, succeeding André C. Muller, who will transition to an advisory role to ensure a smooth leadership change [1][3][4]. Group 1: Leadership Transition - Dr. Srishti Gupta has been a board member since 2021 and is well-positioned to lead the company due to her deep understanding of Idorsia's operations and product portfolio [1][2]. - André C. Muller, the current CEO, will retire and take on an advisory role, having successfully led the company through financial restructuring and the commercial ramp-up of QUVIVIQ in the EUCAN region [3][4]. - The leadership transition aims to maintain stability and continuity as the company focuses on advancing its product portfolio and achieving profitability by the end of 2027 [4][5]. Group 2: Dr. Srishti Gupta's Background - Dr. Gupta has over 20 years of experience in global health and biopharmaceutical innovation, with a strong background in strategy and healthcare systems [2][8]. - She previously spent 18 years at McKinsey & Company, where she held senior leadership roles in the pharmaceutical and global health practices [2][9]. - Dr. Gupta holds an MD from Harvard Medical School and multiple degrees from Harvard University and the University of Cambridge, showcasing her strong academic credentials [8][9]. Group 3: Company Outlook - The company is optimistic about the commercial success of QUVIVIQ, which is gaining traction in Europe, and is reactivating collaboration discussions for TRYVIO [5][12]. - Dr. Gupta emphasizes the need for balancing ambition with financial discipline, indicating a focus on smart investments in promising assets [5][6]. - Idorsia aims to evolve into a leading biopharmaceutical company, committed to discovering and commercializing transformative medicines [11][12].